GATA3 expression in triple‐negative breast cancers

Byrne, David; Deb, Siddhartha; Takano, Elena A.; Fox, Stephen B.

doi:10.1111/his.13187

Cited by 24 publications

(22 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,4,6,12,13 Some studies reported GATA3 expression in >90% of HR-positive cancers, whereas only 20-66% of TNBCs showed expression when a certain clone of GATA3 (L50-823) was used. 6,10,[14][15][16][17] The expression rates of GCDFP15 and MGB in TNBCs were even lower (3-31% and 17-26%, respectively), with many positive cases showing only focal staining. 1,4,6,10,16,18 For these reasons, new markers that are more specific and sensitive for TNBC are needed.…”

Section: Introductionmentioning

confidence: 99%

“…These markers showed high expression in hormonal receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐positive cancers, but low expression in triple‐negative breast cancers (TNBCs) 1,4,6,12,13 . Some studies reported GATA3 expression in >90% of HR‐positive cancers, whereas only 20–66% of TNBCs showed expression when a certain clone of GATA3 (L50‐823) was used 6,10,14–17 . The expression rates of GCDFP15 and MGB in TNBCs were even lower (3–31% and 17–26%, respectively), with many positive cases showing only focal staining 1,4,6,10,16,18 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sry‐related high‐mobility‐group/HMG box 10 (SOX10) as a sensitive marker for triple‐negative breast cancer

Jamidi¹,

Aphivatanasiri

et al. 2020

Histopathology

View full text Add to dashboard Cite

Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer Aims: Confirmation of a breast origin for triple-negative breast cancer (TNBC) is sometimes problematic. The traditional breast markers GATA-binding protein 3 (GATA3), mammaglobin (MGB) and gross cystic disease fluid protein 15 (GCDFP15) have shown limitations in identifying TNBC. Here, we aimed to examine the diagnostic potential of the newly proposed TNBC marker, Sry-related high-mobility-group/HMG box 10 (SOX10). Methods and results: We analysed and compared SOX10 expression with GATA3, MGB and GCDFP15 expression in a test cohort of 1838 invasive breast cancers (IBCs) by using tissue microarrays. The findings from the test cohort were further examined with a validation cohort of 42 TNBCs in whole sections. The overall expression rates of SOX10, GATA3, MGB and GCDFP15 were 6.9%, 83.1%, 47.0%, and 34.8%, respectively. Among the TNBCs within this cohort, the expression rates of SOX10, GATA3, MGB and GCDFP15 were 31.3%, 34.5%, 27.9%, and 25.2%, respectively. SOX10 was strongly associated with TNBC (P < 0.001), whereas all other traditional markers were associated with non-TNBC (P < 0.001 for all). In addition, SOX10 was more correlated to basal-like breast cancer (BLBC) (P = 0.001) than five-marker-negative subtype among the TNBCs. A high expression rate of SOX10 (81%) was confirmed in the validation cohort. Additionally, SOX10 expression was inversely correlated with GATA3 and GCDFP15 expression, so they may complement each other in TNBC detection. The SOX10-GATA3 combination yielded a sensitivity of 60.3% for TNBC detection in the test cohort. Conclusion: SOX10 is a reliable marker for identifying TNBC, and complements GATA3. The SOX10-GATA3 combination may be used as a sensitive TNBC marker.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Sry‐related high‐mobility‐group/HMG box 10 (SOX10) as a sensitive marker for triple‐negative breast cancer

Jamidi¹,

Aphivatanasiri

et al. 2020

Histopathology

View full text Add to dashboard Cite

show abstract

“…GATA3 has been shown to be associated with the luminal subtype of breast cancer, whereas 88% of estrogen receptor (ER)-negative tumors retained GATA3 expression [15]. Its expression rate in triple-negative cancer ranged from 20.16 to 48% [16, 17] in contrast to 74.6% in apocrine type triple-negative breast cancer [18]. The majority of published studies suggest that loss of GATA3 expression is associated with worse prognosis [19]; however, this is not universally accepted [3].…”

Section: Introductionmentioning

confidence: 99%

Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance

Yakirevich

Wang

et al. 2019

BMC Cancer

View full text Add to dashboard Cite

BackgroundCytokeratin 7 (CK7) and GATA binding protein 3 (GATA3) are considered as immunohistochemical hallmarks of breast cancers; however, there are breast tumors lacking these markers. Clinicopathological characterization of CK7 negative breast cancer has not been addressed previously and similar studies on GATA3 negative tumors are limited.MethodsThis study included 196 consecutive cases of Nottingham Grade 3 breast cancers with 159 cases of Grade 1 and Grade 2 tumors for comparison. CK7 and GATA3 expression was correlated with patient’s age, histological type, pathological grade and stage, hormone receptor status, molecular subtype and overall survival.ResultsCK7 negativity was seen in 13% of Grade 3, 9% of Grade 2, and 2% of Grade 1 cases (P = 0.0457). Similarly, 28% of Grade 3, 5% of Grade 2 and 2% of Grade 1 cases were GATA3 negative (P < 0.0001). CK7 negative tumors did not show association with other clinicopathological parameters. GATA3 negative tumors were enriched in the basal-like molecular subgroup and were associated with negative estrogen receptor (ER) and negative progesterone receptor (PR) statuses. Both CK7 and GATA3 expression showed no association with overall survival in patients with Grade 3 tumor.ConclusionsThis is the first study to characterize CK7 negative breast tumors in the context of clinicopathology. Profiling the CK7 negative and GATA3 negative breast cancers helps to understand the biology of these specific tumor subgroups and may aid in their diagnosis.

show abstract

“…GATA3, which is a specific transcription factor of the Th2 cytokine [ 31 ], belongs to the zinc finger structure transcription factor GATA family. GATA1-6 is one of the members that interacts with the common sequence (A/T) GATA (A/G) through higher affinity, and has a DNA-binding motif (zinc finger) [ 32 ]. Studies on GATA3 indicated that GATA3 is critical for the growth and differentiation of T cells.…”

Section: Discussionmentioning

confidence: 99%

Overexpressed GATA3 enhances the sensitivity of colorectal cancer cells to oxaliplatin through regulating MiR-29b

Wang

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background GATA binding protein 3 (GATA3) and miR-29b are related to colorectal cancer (CRC). The current study explored the regulatory relationship between GATA3 and miR-29b, and the mechanism of the two in the drug resistance of CRC cells to oxaliplatin. Method Apoptosis of CRC cells induced by oxaliplatin at various doses was detected by flow cytometry. CRC cells were separately transfected with overexpression and knockdown of GATA3, miR-29b agomir and antagomir, and treated by oxaliplatin to detect the cell viability and apoptosis by performing Cell Couting Kit-8 (CCK-8) and flow cytometry. The expression levels of GATA3, caspase3 and cleaved caspase3 were determined by Western blot, and the expression of miR-29b was detected by quantitative real-time polymerase chain reaction (qRT-PCR). Animal experiments were performed to examine the changes of transplanted tumors in nude mouse xenograft studies and observed by in vivo imaging. TUNEL staining was performed to detect tumor cell apoptosis. Result Both GATA3 and miR-29b agomir inhibited the activity of the CRC cells, promoted apoptosis and Cleaved caspase3 expression, and reduced the resistance of the cells to chemotherapy drug oxaliplatin. Although GATA3 could up-regulate miR-29b expression, the tumor-suppressive effect of GATA3 was partially reversed by miR-29b antagomir. In vivo experiments showed that down-regulating the expression of GATA3 promoted the growth rate and volume of transplanted tumors, while overexpressing GATA3 had no significant effect on tumor growth. TUNEL staining results showed that knocking down or overexpression of GATA3 did not cause significant changes to apoptotic bodies of CRC cells, while oxaliplatin treatment increased the number of apoptotic bodies. Conclusion GATA3 inhibits the cell viability of CRC cells, promotes apoptosis, and reduces oxaliplatin resistance of CRC cells through regulating miR-29b.

show abstract

GATA3 expression in triple‐negative breast cancers

Cited by 24 publications

References 52 publications

Sry‐related high‐mobility‐group/HMG box 10 (SOX10) as a sensitive marker for triple‐negative breast cancer

Sry‐related high‐mobility‐group/HMG box 10 (SOX10) as a sensitive marker for triple‐negative breast cancer

Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance

Overexpressed GATA3 enhances the sensitivity of colorectal cancer cells to oxaliplatin through regulating MiR-29b

Contact Info

Product

Resources

About